



contents in brief

the handbook is divided into the following sections:

- 1** OVERVIEW
The big picture of where we are now and the main challenges we confront.
- 2** AIDS VACCINE SCIENCE
A primer on vaccine research and development.
- 3** CLINICAL TRIALS
How AIDS vaccine candidates are tested in people and what issues arise as individuals, communities and countries engage in the process.
- 4** COMMUNITIES AND COHORTS
Issues specific to certain highly affected and vulnerable communities that are integral to the fight against AIDS.
- 5** GLOBAL ADVOCACY
Policy issues affecting AIDS vaccine development and eventual access, and why advocacy matters.
- 6** VOICES
Insights from people, issues, times and places that have helped shape the AIDS vaccine movement.
- 7** APPENDIX
Detailed listings, including information about the authors, international vaccine trials, participating research agencies and non-governmental organizations (NGOs) involved with AIDS vaccines, and a glossary.

NOTE: Listings of Resources and References to learn more about each subject are located at the end of many chapters. Summaries of the cited references can be found in the PubMed bibliographic database at the US National Library of Medicine: www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
Terms in *bold italics* are defined in the Glossary (Appendix 5).



contents

	FORWARD		i
	an epidemic that rages on	M. Warren	iii
1	OVERVIEW		1
	1 why we need vaccine activism, still	B. Snow	3
	2 where are we in the search for an aids vaccine?	P. Kahn	7
	3 hiv in pictures	P. Kahn/ R. Fernandez-Larsson	15
2	AIDS VACCINE SCIENCE		23
	4 vaccine basics	B. Snow	25
	5 the immune system in pictures	P. Kahn/L. Long	31
	6 vaccine development: from concept to licensed product	H. Collins	37
	7 aids vaccine approaches in development	P. Kahn	45
	8 vaccines that trigger cellular immunity	R. Jefferys	53
	9 partially effective vaccines	E. Bass	59
	10 do clades matter for aids vaccines?	P. Kahn	63
	11 testing aids vaccines in people	E. Bass/P. Kahn	71
	12 testing for immune responses to hiv: the science in pictures	P. Kahn/M. Hoelscher	77
3	CLINICAL TRIALS		85
	13 being a trial volunteer: what happens?	S. Carroll/P. Kahn	87
	14 is it safe?	P. Fast	95
	15 research ethics: recipe for success	B. Snow	103
	16 informed consent in hiv vaccine trials	G. Lindegger	109
	17 community advisory boards	S. Wakefield	117
	18 community education: working together	M. Barbosa de Souza	123
	19 ensuring community participation and readiness: a conversation with janet frölich	P. Kahn	129
	20 vaccine trials: leaving communities better off	AVAC	137
	21 hiv vaccine trials in uganda	P. Kaleebu	145
	22 facing failure on the way towards success: lessons learned from the vaxgen trial	R. Jefferys	153
	23 testing vaccines in injecting drug users: vaxgen's efficacy trial in thailand working with incarcerated participants	P. Kahn M. Martin <i>et al.</i>	161



contents

continued

4	COMMUNITIES AND COHORTS		169
24	women, aids and the search for a vaccine	S. Kapoor	171
25	challenges recruiting women into trials	S. Wakasiaka	179
26	aids research with sex workers: lessons learned	E. Bass	183
27	thai drug users network, aids and human rights: a conversation with karyn kaplan	P. Kahn	191
28	adolescents and aids vaccine research in the usa	A. Smith Rogers	199
29	adolescents in hiv vaccine trials: perspective from botswana	T. Villafana <i>et al.</i>	205
30	testing std vaccines in young people: how it's done	H. Collins	213
31	a queer eye on aids vaccine development	E. Lee	219
32	aids prevention and african militaries: a conversation with colonel deborah birx	P. Kahn	225
5	GLOBAL ADVOCACY		231
33	community matters: (re)-defining our advocacy	S. Mellors	233
34	from trial volunteer to vaccine advocate	P. Wetaka	239
35	speed and equity: why political leadership is important	C. Collins	243
36	ensuring rapid global access to aids vaccines	D. Gold	253
37	just 2 drops: polio eradication in pictures	P. Kahn	261
6	VOICES		273
38	working with communities: 1991	B. Snow	275
39	coming of age amid grief, death and aids	G. Franke-Ruta	281
40	terms of engagement: how communities helped shape brazil's aids vaccine agenda	A. Menezes	285
41	aids, south africa, stigma, vaccines: a conversation with justice edwin cameron	P. Kahn	293
42	going first: a conversation with anthony morris	P. Kahn	299
43	going first: a conversation with mdu nkosi	L. Clarke	305



contents

continued

7	APPENDIX	311
A1	the authors	313
A2	trial sites around the world	323
A3	ongoing clinical trials	325
A4	organizations involved with aids vaccines about AVAC	329 343
A5	glossary	345
	INDEX	363

TABLES AND FIGURES

0.1	global estimates of adults and children living with hiv (2004)	vii
1.1	developing vaccines: how long it takes	8
2.1	pipeline of vaccine research and development	36
2.2	types of vaccines in clinical trials (february 2005)	47
2.3	clades / uganda	64
2.4	clades / thailand	66
2.5	clades / cameroon	67
3.1	common CAB activities	121
3.2	examples of community preparedness activities	132
3.3	critical activities of a community mobilization and education strategy	134
3.4	race, gender and the VAX004 trial volunteers	155
3.5	VAX004 trial results: infection rates in vaccine and placebo groups	156
5.1	annual deaths from vaccine-preventable diseases (2002)	258
6.1	milestones for community involvement with aids vaccines in brazil	290
7.1	countries conducting aids vaccine trials (february 2005)	322-3
7.2	preventive aids vaccines in clinical trials (february 2005)	324-7